## IAF12 Rac'd PCT/FTO J 7 FEB 2006

Unassigned

084335-0201

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

nder (ne r aperwork	Reduction Act of 1995, no persons are required to re Substitute for form 1449B/PTO	spond to a concentration of anothericas it conte	U.S. Patent and Trademark Office: [1.3]. DEPANYM ins a valid OMB control number. Complete if Known	
	INFORMATION DISCLOSURE	Application Number	Unassigned	
	STATEMENT BY APPLICANT	Filing Date	February 7, 2006	
	Date Submitted: February 7, 2006	First Named Inventor	Makoto SAWADA	
		Group Art Unit	Unassigned	

Attorney Docket Number

Examiner Name

(use as many sheets as necessary)

Sheet

_	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant		
	No.1	Number	Kind Code <sup>2</sup> ( <i>if</i> known)	Document	Cited Document MM-DD-YYYY	. Figures Appear		

					FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document		ument	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
		Office	3 Number4	Kind Code <sup>5</sup> ( <i>if known</i> )	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	Te
	A1	WO	2004/015392 A2		TARGETED MOLECULES CORP.	2/19/2004		-

		NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.		I item (book magazine journal serial symnosium catalog etc.) date nagels) volume-issue numberis) nublisher city and/or country where					
	A2	R. PASQUALINI et al., "Organ targeting in vivo using phage display in vivo using phage display peptide libraries", Nature, 1996, Vol. 380, No. 6572, pp. 364-366.					
, 12 	A3	S.R. SCHWARZE, et al., "In vivo protein transduction: delivery of a biologically active protein into the mouse", Science, 1999, Vol. 285, No. 5433, pp. 1569-1572.					
	A4	YOUNG-SOOK KANG et al., "Stability of the Disulfide Bond in an Avidin-Biotin Linked Chimeric Peptide During in vivo Transcytosis Through Brain Endothelial Cells", Journal of Drug Targeting, 2000, Vol. 8, No. 6, pp. 425-434.					
	A5	Makoto SAWADA et al., "Brain-specific gene expression by immortalized microglial cell-mediated gene transfer in the mammalian brain", FEBS Letters, 1998, Vol. 433, pp. 37-40.					
<u>s Ēv </u>							
Section 1							

Examiner Signature		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.